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Abstract: The dramatic rise in allergic disease has occurred in tandem with recent environmental
changes and increasing indoor lifestyle culture. While multifactorial, one consistent allergy risk
factor has been reduced sunlight exposure. However, vitamin D supplementation studies have
been disappointing in preventing allergy, raising possible independent effects of ultraviolet (UV)
light exposure. The aim of this study was to examine whether UV light exposure influences the
development of allergic disease in early childhood. Direct sunlight exposure (290–380 nm) in early
infancy was measured via UV dosimeters. Outdoor exposure, sun protective behaviours, and allergy
outcomes were assessed over the first 2.5 years of life with clinical assessment appointments at 3,
6, 12 and 30 months of age. Children with eczema had less (p = 0.038) direct UV light exposure
between 0–3 months of age (median (IQR) 747 (473–1439) J/m2) than children without eczema
(median (IQR) 1204 (1717–1843) J/m2); and less outdoor exposure time (7 min/day) between 11 a.m.
and 3 p.m. compared to children without eczema (20 min/day, p = 0.011). These associations were
seen independent of vitamin D status, and after adjusting for other potential confounders. Whilst we
could not find any associations between direct UV light exposure and other allergic disease outcomes,
exposure to UV light appears to be beneficial in reducing the risk of eczema development in early
childhood. Further research is required to determine optimal levels of UV light exposure while
balancing the potential risks.
Keywords: allergy prevention; eczema; atopic dermatitis; wheeze; food allergy; allergic rhinocon-
junctivitis; allergen sensitisation; early childhood; sunlight
1. Introduction
The prevalence of allergic disease has dramatically increased over recent decades.
Genetic factors certainly play a role in the genesis of allergic diseases, but cannot explain
the rapid increase seen over this period. When looking for potential factors driving the
increasing risk of allergic disease development, the environmental and lifestyle changes
of the modern age are clearly implicated [1–4]. While previously largely an issue in
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developed countries, the more recent rise of allergic disease in developing countries adds
further evidence of the likely impact of increasing urbanization on disease risk [4,5]. While
environmental changes are multifactorial, one consistent factor has been a shift from
an outdoor to an increasingly indoor lifestyle culture, with greater reliance on digital
technology for work and recreation. This global phenomenon [6] affecting all age groups,
including during pregnancy and infancy [7–9], has led to reduced levels of UV light
exposure. UV light plays a crucial role in vitamin D synthesis with an estimated 90 to 95%
of human vitamin D provided by cutaneous synthesis under the influence of UVB light [7].
Hence, it is not unexpected that vitamin D deficiency and insufficiency have become global
issues—now afflicting more than one billion people globally [7,10–14], including during
the critical periods of development of pregnancy and infancy [14–17].
Considering the known immunomodulatory properties of vitamin D [18,19], this has
been a logical pathway to explain the increasing propensity for allergic disease [20–22].
However, while epidemiological associations between sunlight exposure (as a surrogate
marker of vitamin D status) seemed promising [23–25], randomized controlled trials (RCTs)
using oral vitamin D supplementation for allergy prevention during pregnancy [26,27] or
infancy [28,29] have been disappointing, suggesting that the protective effects of sunlight
may be operating through other pathways. Specifically, these trials found limited or no
effect on child allergic disease outcomes. A meta-analysis of the pregnancy supplementa-
tion RCTs [30] found no overall effect on risk of early childhood (≤4 years of age) atopic
dermatitis (3 trials, n = 1538, with 357 cases, relative risk 0.92 (95% confidence intervals
0.77; 1.11) or recurrent wheeze (4 trials, n = 1781, with 358 cases, relative risk 0.76 (95% con-
fidence intervals 0.54; 1.08). Thus, attempting to increase vitamin D status using vitamin D
supplementation in pregnancy or infancy as an allergy prevention strategy has yet to be
shown to be beneficial.
For this reason, there has been growing speculation that the epidemiological associa-
tions [23–25] between reduced sunlight exposure and increased risk of allergic disease may
be mediated, at least in part, through immunological consequences of decreased direct
UV light exposure rather than vitamin D alone. Indeed, increasing evidence from the field
of photobiology has found that UV light can induce immunomodulative effects [31,32].
Exposure to UV light directly induces epidermal cells in the stratum corneum to produce
multiple mediators that modulate cutaneous dendritic cells. In turn, these regulate T cell-
dependent responses in the skin-draining lymph nodes, with less induction of effector
memory cells, and greater production and increased function of T and B regulatory cells.
Skin dendritic cells induce peripheral T regulatory cells which migrate from lymph nodes
into circulation and back to UV-irradiated skin where they reduce inflammation associated
with skin disease [32–34]. Likely mechanisms for immunomodulation also include the
release of bioactive molecules, such as urocanic acid, from epidermal cells after direct UV
light exposure [35,36]. It has been proposed that cis-urocanic acid modulates the produc-
tion of immunosuppressive molecules which activate T regulatory cells in the lymph nodes
and are released into the systemic circulation to reduce inflammatory responses to anti-
gens [31,32]. This ability for cis-urocanic acid to be systemically immunosuppressive has
been supported by a study showing a reduced dermal allergic hypersensitivity response
after UV exposure [37].
In this study, considering these potential direct immunomodulatory influences of
UV light in the context of early life as a critical time for allergy development [20–22,38],
we sought to further explore whether early life exposure to UV light had vitamin D-
independent effects on early childhood allergy outcomes. Specifically, we aimed to examine
whether direct UV light exposure (measured by a personal UV dosimeter) in the first
3 months of life reduces the risk of allergic disease in the first 2.5 years of life, and to
explore whether sunlight exposure and sun protecting behaviours in early childhood may
influence the development of allergic disease in the first 2.5 years of life.
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2. Materials and Methods
2.1. Study Design
This is an exploratory analysis of data collected as part of a double-blinded RCT inves-
tigating the effect of infant oral vitamin D supplementation for the first 6 months of infancy
on allergic disease outcomes. Full details of participant screening and infant outcomes to
the end of the intervention period at 6 months of age have been previously published [28].
Infant inclusion criteria were term delivery (>37 weeks of gestation) and a family his-
tory (parent and/or sibling) of allergic disease, while exclusion criteria were underlying
maternal autoimmune disease or immunodeficiency, and maternal 25-hydroxyvitamin
D (25(OH)D) level <50 nmol/L or >100 nmol/L at 36–40 weeks of gestation. Written
informed consent was obtained before trial participation and included consent to par-
ticipate in follow-up clinical assessments at 1 and 2.5 years of age. Follow up results
of this RCT have also already been published [29] and revealed that infant oral vitamin
D supplementation (400 IU cholecalciferol/day) over the first 6 months of life had no
influence on allergic disease outcomes over the first 2.5 years of life. Human Research
Ethics Committee approvals were granted by the Princess Margaret Hospital for Children
(approval number 1959/EP) and the University of Western Australia (approval number
RA/4/1/5566). The trial was registered with the Australian New Zealand Clinical Trials
Registry (ACTRN12612000787886).
2.2. Direct UV Light Exposure Measurements
UV dosimeters (VioSpor blue line Type II, Biosense, Bornheim, Germany) were issued
to a subset of the RCT participants, with the aim to obtain objective, quantitative data on
individual infant UV light exposure from 0–3 months of age [39–41] and provide data on
the total UV light (290–380 nm) exposure dose (in joule per square meter [J/m2]). Due to
funding constraints, we were unable to provide UV dosimeters to all infants participating
in the RCT but allocated them to the first 3–4 infants enrolled per month over the course
of two years, to distribute the data collection over the 12 months of each year and over
the four seasons (summer, autumn, winter and spring). Compliance with the daily UV
dosimeter use was captured on diary cards completed by a parent/guardian.
2.3. Sunlight Exposure and Sun Protecting Behaviours
At 3 months, 6 months, 1 year and 2.5 years of age, a parent/guardian of all RCT
participants (both those allocated a UV dosimeter and those without) were asked questions
to capture details on the child’s outdoor and sunlight exposure during the preceding week.
We collected parent-reported details on any sun protective behaviours, including frequency
of use of sunscreen (always, sometimes or never) and which sun protection factor (SPF) was
used. Questions were based on the sunlight exposure questionnaire by Cargill et al. [42].
Details collected also included the question “What time of the day do you take your baby
outdoors” distinguishing between estimated averaged time (in minutes/day) spent in:
1. direct sunlight before 11 a.m., between 11 a.m. and 3 p.m., and after 3 p.m.
2. in shade before 11 a.m., between 11 a.m. and 3 p.m., and after 3 p.m.
Questions also assessed the parent-reported average amount of skin exposed to
sunlight by body parts (face and hands, or face, hands and arms, or face, hands, arms and
legs). In addition, the skin type of each participant (type I to VI, Fitzpatrick scale [43]) was
assessed to estimate the possible variable response of different types of skin to UV light.
2.4. Vitamin D Supplementation
Vitamin D supplementation ingested doses during the intervention phase of the RCT
for each infant participant were calculated during the first 3 months, and from 3 to 6 months
of life. The daily dose of vitamin D (400 IU) of the intervention group was based on parent-
documented diary card reporting (completed to assess study product compliance) and
monthly standardized questions which were also asked by our research team regarding
any oral vitamin D supplement intake independent of the trial product use. In addition,
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information was also captured regarding medically indicated vitamin D supplementation,
as all infants with a 25(OH)D level of < 50 nmol/L at 3 months of age were supplemented
with appropriate treatment doses of vitamin D.
2.5. Allergic Disease Outcome Assessments
At 3 months, 6 months, 1 year and 2.5 years of age the participating children were
assessed by a Paediatric Clinical Immunologist at the Princess Margaret Hospital in Perth,
Australia. A structured history and a standardized clinical examination to diagnose any
allergic diseases were performed. In addition, written reports regarding any hospital
presentations/admissions, previous medical reports/assessments and the use of allergy re-
lated medications were considered by the assessing immunologist. At 1 and 2.5 years of age,
skin prick testing (SPT) was performed using commercially available standardized allergen
extracts to the most common allergens amongst young Australian children, including cow’s
milk, hen’s egg, peanut, cashew nut, wheat, tuna, house dust mite (Dermatophagoides
pteronyssinus), cat and rye grass pollen on the day of clinical assessment. Sensitization
was defined as a positive SPT (wheal ≥ 3 mm above negative control) to at least one of the
allergens assessed. The participants were assessed for eczema [44], asthma/wheeze, and
food allergy at 3 months, 6 months, 1 year and 2.5 years of age. At 2.5 years of age only,
the participants were also assessed for a medical diagnosis of allergic rhinoconjunctivitis.
Eczema was defined according to the criteria of Hanifin et al. [45] on medical review or
when a typical history was taken of an itchy rash distributed to the facial, extensor or
flexural surface of the skin following a chronic or fluctuating course. Eczema severity
was assessed using the SCORAD index [46] (skin area affected, intensity and subjective
symptoms) at each clinical assessment appointment (at 3, 6, 12 and 30 months of age). IgE-
mediated food allergy was defined by a history of an immediate (within 90 min) skin rash
(urticaria, erythema), angioedema, gastrointestinal symptoms (abdominal pain, vomiting,
diarrhea) and/or irritability associated with or without cardiovascular symptoms (collapse)
and/or respiratory symptoms (wheeze, stridor, persistent cough, hoarse voice) following
the ingestion of a specific food trigger combined with a matching specific food allergen
sensitization. Wheeze was defined by a history of an audible wheeze responding to inhaled
beta2-agonists. Asthma was defined in children over one year of age only, with a history
of recurrent wheeze responding to inhaled beta2-agonists and/or use of a preventer for
symptom control. Allergic rhinoconjunctivitis was defined in children over one year of age
only with as a history of sneezing or blocked/ runny nose accompanied by itchy or watery/
red eyes unrelated to an upper respiratory tract infection. When wheeze/asthma or allergic
rhinoconjunctivitis was combined with sensitization, it was defined as IgE-associated.
2.6. Statistical Methods
Statistical analysis was performed using IBM SPSS Statistics for Windows, version
26 (IBM Corp., Armonk, NY, USA). Data was examined to be missing at random, with an
available case analysis approach utilized and respective participant numbers (n) reported
throughout. While a pairwise case-by-case analysis approach resulted in maximizing
power for analysis, this also presented fluctuations in participant numbers (n) available
for each analysis reported which should be considered when interpreting these results.
All tests were two-sided, with a p < 0.05 considered statistically significant. Categorical
data was described using count and percent (%). Scale data was described using mean
(M), standard deviation (SD), median (Md), or interquartile range (IQR) with normality
assessed using the Shapiro–Wilk test. Between group differences were examined between
dosimeter worn and not worn, and between allergic disease and no allergic disease. For
categorical variables, these group differences were compared using Chi-Square with a
Fisher’s exact 2-sided p-value reported. For continuous variables, these were computed
using Mann–Whitney U test (not normally distributed), except for birth weight which was
normally distributed and assessed using an independent samples t-test.
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For the dosimeter worn only group, a generalized linear model with binomial proba-
bility distribution and logit link function was used to examine the influence of direct UV
light exposure in the first three months (covariate) on the development of allergic disease
within the first 2.5 years of life (dependent variable yes/no), with confounders season of
birth, skin type, and vitamin supplementation (yes/no). The odds ratio (OR), 95% Wald
confidence intervals (CI) and significance reported, and Bonferroni corrected pairwise
comparison were conducted as appropriate. The relationship between direct UV light
exposure (measured by UV dosimeter over the first 3 months of life) and eczema severity
(measure by SCORAD Score) was investigated using Spearman rho correlation coefficients.
Generalized linear mixed models (GLMM) (binomial distribution with a logit link)
were used to examine the changes over the four time points (3 months, 6 months, 1 year and
2.5 years) for each of the binary outcomes (present/absent): eczema, wheeze or any allergic
disease (atopy). The models included time as the repeated measure. An unstructured
random effect for participants was included for the atopy models only. Fixed effects for con-
founding variables were examined in individual (unadjusted) models (due to sample size
limitations) to identify potential confounding: skin type (due to low numbers Fitzpatrick
categories I to VI were these collapsed to pale/normal/dark), season of birth, vitamin D
levels, outdoor exposure (minutes), sunscreen use (always/sometimes/never) and skin
exposed (face/face, hands, arms/face, hands, arms and legs). The model used an un-
structured repeated covariance structure, with a robust estimation for model assumptions.
Sequential Bonferroni corrected p-values are reported. A final adjusted GLMM model was
conducted with all significant confounders identified from the unadjusted models.
3. Results
3.1. Characteristics of the Study Population
Table 1 summarizes the baseline demographic details comparing the infants who
were allocated the UV dosimeters (n = 86) to those who were not (n = 109). There were no
significant differences between these groups of infants, apart from an increased prevalence
of maternal history of allergic disease in the group who were not allocated a UV dosimeter,
and differences in season of birth of the infants allocated a UV dosimeter compared to
those who were not. Study participant flow details from randomisation to 2.5 years of age
follow-up have been previously published [29].
3.2. Clinical Allergic Disease Outcomes
The most common allergic disease in the first 2.5 years of life was eczema, affecting
a total of 49.1% (81/164) children. By 2.5 years of age, 22.8% (31/136) of the participants
were sensitized to at least one allergen, 16.8% (27/161) had medically diagnosed allergic
rhinoconjunctivitis and 43.8% (71/162) had medically diagnosed wheeze (see methods
Section 2.5). At one year of age, 6.3% (11/175) children were diagnosed with IgE-mediated
food allergy and 5.6% (9/162) at the 2.5 year follow up. Egg allergy was the most common
food allergy, affecting 9/175 (5.1%) infants in the first year and as expected this had reduced
to 5/162 (3.1%) at 2.5 years of age.
3.3. Association between Direct UV Light Exposure in Early Infancy and Allergic Disease
Outcomes in the First 2.5 Years of Life
Non-compliance with use of the UV dosimeter occurred with three infants (none
of whom developed eczema within the first 3 months of life), leaving 83 infants with
useable UV light exposure data. Median (IQR) UV light exposure measured by the UV
dosimeters was 950 (556–1577) J/m2 from 0–3 months of age, typically with face, hands
and arms exposed.
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Table 1. Baseline Characteristics: comparing infants who wore the UV dosimeter for the first 3 months
(n = 86) to those who did not wear the UV dosimeter (n = 109).
Characteristic UV Dosimeter not Wornn (%)
UV Dosimeter Worn
n (%) p-Value
Mother completed high school 100/108 (92.6) 83/86 (96.5) 0.35
Maternal white race 90/109 (82.6) 70/86 (81.4) 0.96
Maternal allergic disease 90/108 (83.3) 60/86 (69.8) 0.04
Paternal allergic disease 78/108 (72.2) 68/85 (80.0) 0.24
Infant male sex 58/109 (53.2) 46/86 (53.5) 0.99
Infant birth weight (grams) 3438 ± 374 3395 ± 363 0.42 a
Caesarean-section birth 43/109 (39.4) 32/86 (37.2) 0.77
Infant season of birth
<0.001
Summer 13/109 (11.9) 17/86 (19.8)
Autumn 18/109 (16.5) 26/86 (30.2)
Winter 24/109 (22.0) 33/86 (38.4)
Spring 54/109 (49.5) 10/86 (11.6)
Infant Fitzpatrick Skin Type
0.81
Type I 1/95 (1.1) 1/84 (1.2)
Type II 27/95 (28.4) 22/84 (26.2)
Type III 51/95 (53.7) 40/84 (47.6)
Type IV 13/95 (13.7) 17/84 (20.2)
Type V and VI 3/95 (3.2) 4/84 (4.8)
Smoking in home 6/108 (5.6) 8/85 (9.4) 0.40
Pet cat indoors 17/108 (15.7) 15/85 (17.6) 0.85
Pet dog indoors 56/108 (51.9) 51/85 (60.0) 0.31
Note: a Group difference t-test statistic reported.
Sixteen infants had medically diagnosed eczema between 0 to 6 months of age, and as
previously published we found an inverse association between direct UV light exposure
and eczema outcome at 6 months of age, but no association with wheeze symptoms [28].
Another 24 new cases of eczema were medically diagnosed between 6 months and 2.5 years
of age in the subgroup of participants who wore a UV dosimeters in early infancy.
Consistent with previously found eczema outcomes at 6 months of age [28] children
with cumulative (birth to 2.5 years of age) medically diagnosed eczema had significantly
less direct UV light exposure between 0 to 3 months of age (median (IQR) 747 (473–1439)
J/m2) than children without eczema (median (IQR) 1204 (1717–1843 J/m2) (U −2.07;
p = 0.038) (Figure 1, Table 2). There were no associations found between UV light exposure
levels within the first 3 months of life and eczema severity SCORAD scores at 3 months
(r = −0.20, p = 0.08), 6 months (r = −0.19, p = 0.09), 1 year (r = −0.14, p = 0.23) and 2.5 year
follow up appointments (r = −0.14, p = 0.26).
No significant differences in UV light exposure in early infancy were found between
children who had medically diagnosed asthma/wheeze, food allergy or allergic rhinocon-
junctivitis, compared to those who did not, within the first 2.5 years of life (Figure 1).
3.4. Cross-Sectional Associations between Behaviours Concerning Sun Exposure and Allergic
Outcomes within the First 2.5 Years of Life
Total estimated outdoor exposure time by parental report at 3, 6 and 12 months, as
well as at 2.5 years of age, was not significantly different between children who developed
eczema or any other allergic outcomes within the first 2.5 years of life (Tables 2 and 3).
This also applied for time in the shade or time in the sun exposure in isolation (p > 0.05).
Examining potential confounding factors at the different time periods such as vitamin
D levels, oral vitamin D intake, sunscreen use, exposed skin area, skin type and season
of birth, again found no significant differences for cumulative eczema or other allergy
outcomes within the first 2.5 years of life (Tables 2 and 3).
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Figure 1. The influence of direct UV light exposure on allergy outcome.
Table 2. Comparison of cumulative eczema outcomes by 2.5 years of age in association to examined
key risk factors.
Outcome No Eczema (n = 84) Eczema (n = 81)
n Median (IQR) n Median (IQR) p-Value
UV exposure 0–3 months (J/m2) 39 1204.0 (717–1843) 40 747.0 (473–1439) 0.038
25(OH)D blood 3 months 65 71.0 (58–90) 62 72.5 (55–88) 0.75
levels (nmol/L) 6 months 69 89.0 (75–106) 63 87.0 (65–112) 0.61
12 months 73 78.0 (66–92) 70 78.0 (62–94) 0.80
30 months 68 75.0 (65–88) 56 74.0 (60–88) 0.77
Total outdoor exposure 3 months 84 75.0 (50–116) 79 65.0 (42–105) 0.41
time (minutes/day) 6 months 83 66.0 (40–115) 76 75.0 (41–120) 0.92
12 months 81 100.0 (65–150) 74 90.0 (60–125) 0.48
30 months 83 150.0 (105–225) 75 160.0 (120–210) 0.50
n (%) n (%) p-value
Sunscreen used (3 months) Always 2/84 (2.4) 3/79 (3.8)
Sometimes 22/84 (26.2) 14/79 (17.7) 0.46 a
Never 60/84 (71.4) 62/79 (78.5)
Sunscreen used (6 months) Always 10/83 (12.0) 8/78 (10.3)
Sometimes 41/83 (49.4) 29/78 (37.2) 0.21
Never 32/83 (38.6) 41/78 (52.6)
Sunscreen used (12 months) Always 14/81 (17.3) 14/78 (17.9)
Sometimes 52/81 (64.2) 41/78 (52.6) 0.24
Never 15/81 (18.5) 23/78 (29.5)
Sunscreen used (30 months) Always 29/84 (34.5) 28/76 (36.8)
Sometimes 53/84 (63.1) 44/76 (57.9) 0.58
Never 2/84 (2.4) 4/76 (5.3)
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Table 2. Cont.
Skin exposed (3 months) Face 34/84 (40.5) 37/79 (46.8)
Face, hands and arms 10/84 (11.9) 8/79 (10.1) 0.73
Face, hands, arms and legs 40/84 (47.6) 34/79 (43.0)
Skin exposed (6 months) Face 32/83 (38.6) 26/78 (33.3)
Face, hands and arms 12/83 (14.5) 9/78 (11.5) 0.58
Face, hands, arms and legs 39/83 (47.0) 43/78 (55.1)
Skin exposed (12 months) Face 27/80 (33.8) 25/78 (32.1)
Face, hands and arms 22/80 (27.5) 19/78 (24.4) 0.84
Face, hands, arms and legs 31/80 (38.8) 34/78 (43.6)
Skin exposed (30 months) Face 7/84 (8.3) 10/76 (13.2)
Face, hands and arms 37/84 (44.0) 35/76 (46.1) 0.51
Face, hands, arms and legs 40/84 (47.6) 31/76 (40.8)
Season of birth summer 13/84 (15.5) 15/81 (18.5)
autumn 19/84 (22.6) 18/81 (22.2) 0.89
winter 23/84 (27.4) 24/81 (29.6)
spring 29/84 (34.5) 24/81 (29.6)
Note: a Fisher’s Exact Chi-Square test statistic reported as cell count less than five.
Table 3. Comparison of cumulative allergic outcomes within first 2.5 years of life in association to key risk factors.
Outcome Non-Allergic (n = 69) Allergic (n = 92)
n Median (IQR) n Median (IQR) p-Value
UV exposure 0–3 months (J/m2) 32 1174.5 (581–1818) 46 812.5 (511–1380) 0.11
25(OH)D blood 3 months 51 67.0 (56–83) 73 73.0 (57–91) 0.24
levels (nmol/L) 6 months 54 89.5 (74–106) 75 86.0 (67–107) 0.50
12 months 60 78.0 (66–92) 79 78.0 (61–92) 0.99
30 months 52 74.5 (62–87) 72 75.0 (65–89) 0.44
Total outdoor exposure 3 months 69 65.0 45–93) 90 70.0 (50–111) 0.63
time (minutes/day) 6 months 67 70.0 (40–125) 88 75.0 (46–104) 0.68
12 months 66 105.0 (65–166) 85 90.0 (63–125) 0.33
30 months 68 150.0 (113–210) 91 150.0 (120–240) 0.64
n (%) n (%) p-value
Sunscreen (3 months) Always 0/69 (0.0) 5/90 (5.6)
Sometimes 16/69 (23.2) 18/90 (20.0) 0.13
Never 53/69 (76.8) 67/90 (74.4)
Sunscreen (6 months) Always 6/68 (8.8) 11/89 (12.4)
Sometimes 32/68 (47.1) 37/89 (41.6) 0.74
Never 30/68 (44.1) 41/89 (46.1)
Sunscreen (12 months) Always 10/67 (14.9) 17/88 (19.3)
Sometimes 46/67 (68.7) 47/88 (53.4) 0.16
Never 11/67 (16.4) 24/88 (27.3)
Sunscreen (30 months) Always 24/69 (34.8) 34/92 (37.0)
Sometimes 43/69 (62.3) 54/92 (58.7) 0.84
Never 2/69 (2.9) 4/92 (4.3)
Skin exposed (3 months) Face 29/69 (42.0) 42/90 (46.7)
Face, hands and arms 8/69 (11.6) 8/90 (8.9) 0.78
Face, hands, arms + legs 32/69 (46.4) 40/90 (44.4)
Skin exposed (6 months) Face 25/68 (36.8) 32/89 (36.0)
Face, hands and arms 10/68 (14.7) 11/89 (12.4) 0.88
Face, hands, arms + legs 33/68 (48.5) 46/89 (51.7)
Skin exposed (12 months) Face 26/66 (39.4) 27/88 (30.7)
Face, hands and arms 17/66 (25.8) 21/88 (23.9) 0.39
Face, hands, arms + legs 23/66 (34.8) 40/88 (45.5)
Skin exposed (30 months) Face 7/69 (10.1) 11/92 (12.0)
Face, hands and arms 30/69 (43.5) 43/92 (46.7) 0.85
Face, hands, arms + legs 32/69 (46.4) 38/92 (41.3)
Season of birth summer 10/69 (14.5) 16/92 (17.4)
autumn 16/69 (23.2) 21/92 (22.8) 0.92
winter 21/69 (30.4) 24/92 (26.1)
spring 22/69 (31.9) 31/92 (33.7)
However, focusing on each specific single time period (time spent outdoors before
11 a.m., between 11 a.m. to 3 p.m., or after 3 p.m.) children with eczema diagnosed over the
first 2.5 years of life had significantly less outdoor exposure (n = 79; mean = 7 ± 21.6 min/day)
within the first 3 months of life between 11 a.m. and 3 p.m., compared to children with-
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out eczema (n = 84; mean = 20 ± 29.1 min/day, p = 0.01). Figure 2 includes an illustrated
summary of this eczema outcome finding.
Figure 2. An illustrated summary of the major factors within the first 2.5 years of life that were
associated with medically diagnosed eczema and wheeze outcomes.
Whereas the group of children developing at least one allergic disease within the
first 2.5 years of life spent significantly more time outdoors before 11 a.m. within the
first 3 months of life (n = 90, mean = 30 ± 29.9 min/day) than the group who did not
develop any allergic diseases (n = 69; mean = 15 ± 31.0 min/day, p = 0.03). There were
no other significant associations concerning the other time periods spent outdoors (before
11 a.m./between 11 a.m. and 3 p.m./ after 3 p.m.) combined with the participant age
groups (0 to 3 months/3 to 6 months/6 to 12 months/1 year to 2.5 years) or specifically
time spent in the shade or sun and eczema or other allergic disease outcomes over the first
2.5 years. Again examining potential confounding factors, including vitamin D levels, oral
vitamin D intake, sunscreen use, exposed skin, skin type and season of birth, no significant
eczema or allergy outcome group differences within the first 2.5 years of age were detected
at each of the different time periods.
3.5. Longitudinal Associations between Behaviours Concerning Sun Exposure and Clinical
Allergic Outcomes during Early Childhood: Mixed-Effects Logistic Regression Modeling
GLMM for each confounder were examined in individual unadjusted any allergic
disease outcome models (any allergic disease development within the first 2.5 years of
life). No significant fixed effects were detected for skin type (F = 0.54, p = 0.58); season
of birth (F = 0.43, p = 0.73), or vitamin D levels (F = 3.60 p = 0.06). Children that were
given vitamin D supplementation for the first 3 months of life (F = 20.6, p < 0.001) were at
increased risk of any allergic disease (OR = 1.03 CI 1.02–1.04). However, this result did not
remain significant after the final GLMM, which included confounding factors. Protective
fixed effects included outdoor daily sun exposure time (F = 32.0, p < 0.001, OR = 0.98 CI
0.98–0.99), sunscreen use (F = 9.51, p < 0.001) for always (OR = 0.38, CI 0.23–0.64, p < 0.001)
and sometimes (OR = 0.45, CI 0.29–0.68, p < 0.001) compared to never. The final GLMM
examined any allergic disease with adjustments for confounders and found significant
effects for daily outdoor sun exposure, sunscreen and skin exposed (Table 4).
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Table 4. Generalised Linear Mixed Models (binary logit link function) for outcomes any allergic
disease, eczema and wheeze.
Model Term p-Value OR 95% CI for OR
Lower Upper
Any Allergic Disease Model
Daily sun exposure <0.001 0.987 0.981 0.992
Sunscreen always a 0.05 0.494 0.244 1.000
Sunscreen sometimes a 0.02 0.499 0.279 0.892
Skin exposed face b 0.06 0.589 0.339 1.025
Skin exposed face, hands and arms b 0.01 0.469 0.261 0.841
Vitamin D supplementation 0.11 0.992 0.983 1.002
Eczema Model
Sunscreen always a 0.40 1.239 0.752 2.039
Sunscreen sometimes a 0.009 1.566 1.117 2.196
Wheeze Model
Season of birth summer c 0.64 1.197 0.569 2.516
autumn c 0.009 0.417 0.217 0.800
winter c 0.49 0.810 0.444 1.478
Outdoor exposure 0.005 0.996 0.993 0.999
Note: OR odds ratio; a compared to never; b compared to face, hands, arms and legs; c compared to spring.
Individual unadjusted eczema outcome models reported no significant fixed effects
detected for skin type (F = 0.60, p = 0.55); season of birth (F = 0.20, p = 0.90), vitamin D levels
(F = 0.12, p = 0.73), vitamin D supplementation in the first 3 months (F = 0.05, p = 0.82);
outdoor exposure (F = 0.10, p = 0.75), daily sun exposure (F = 0.15, p = 0.70); daily shade
exposure (F = 0.001, p = 0.98); and skin exposed (F = 0.15, p = 0.86). Only sunscreen was a
significant confounder (F = 3.41, p = 0.03) where children who sometimes wore sunscreen
(as opposed to always or never) were at increased risk of eczema (OR = 1.57, CI 1.12–2.20,
p = 0.009) (Table 4). All children who wore sunscreen used SPF 50.
Wheeze unadjusted models for each confounder were examined with no significant
fixed effects detected for skin type (F = 0.49, p = 0.61), vitamin D levels (F = 0.18, p = 0.67),
vitamin D supplementation in the first 3 months (F = 3.8, p = 0.05); sunscreen (F = 1.59,
p = 0.20), skin exposed (F = 2.77, p = 0.06) or daily shade exposure (F = 2.46, p = 0.12).
Protective fixed effects included season of birth (F = 3.35, p = 0.02) with a decreased risk
of wheeze for children born in autumn (OR = 0.39, CI 0.20–0.75, p = 0.005), time spent
outdoors (F = 9.1, p = 0.003, OR = 1.00, CI 0.99–1.00) and increased daily sun exposure
(F = 8.18, p = 0.004, OR = 0.91, CI 0.86–0.97). Figure 2 includes an illustrated summary
of these wheeze outcome findings. The final adjusted GLMM examined wheeze with
confounders season of birth and outdoor exposure, with both remaining significant effects
and summarised in Table 4.
Longitudinal modelling was not possible to be conducted for allergic rhinoconjunc-
tivitis and allergen sensitisation, as these were not collected at all four time points; while
for food allergy the number of food allergic children was too small to be examined (n = 15
by 2.5 years of age).
4. Discussion
This exploratory analysis confirms our previous observations that increased direct
UV light exposure in the first three months of life appears to decrease the risk of eczema
development [28]. These findings are further supported by parent-reported increased time
spent outdoors within the first 3 months of life between 11 a.m. and 3 p.m. (typically the
highest UV light exposure time period each day in Australia) with reduced child eczema
outcomes over the first 2.5 years of life. In short, the effects of early infancy direct UV light
exposure appear to have continuing benefits on reducing eczema development risk into
early childhood.
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Our findings are supported by cohort studies in the United States [47], Spain [48] and
Korea [49], where associations were also observed between eczema prevalence in childhood
and mean annual UV indices [47], number of sunny hours in a geographical region [48],
or season of birth with estimated UV exposure [49]. A major strength of our study is that
we uniquely also measured individual direct UV light exposures using personalized UV
dosimeters. This provided objective quantifiable UV light exposure data to correlate with
individual child eczema outcomes. Although, due to funding constraints, we were only
able to use these personalized UV dosimeters in a sub-set of our trial participants from birth
to three months of age, we still found a significant association with early childhood eczema
outcomes. We recognize that there was an unbalanced distribution of infants allocated an
UV dosimeter according to season of birth. This resulted from variable rates of recruitment
in some months each year. We would recommend the use of UV dosimeters (or similar
devices) to capture direct individual UV light exposure levels in larger future studies,
where extending their use to other time periods during infancy and early childhood should
enable further clarification of critical time periods where direct UV light exposure may
influence allergic disease outcomes. Future studies would also benefit with the inclusion
of genetic profiling of the study participants. For example, examining filaggrin (FLG)
gene mutation variants in association with variable UV light exposure levels may further
enhance our understanding of this field.
We demonstrated an association of more UV light exposure with reduced eczema
outcomes in early childhood, but it remains to be shown as to what extent specifically UVA
and/or UVB light is responsible for our observed findings. In this context, it also needs to
be considered that our data revealed a longitudinally protective role of sunscreen use for
the development of eczema if used sometimes, compared to always when outdoors over the
first 2.5 years of life. This finding was unexpected and initially inconsistent with the general
understanding that sunscreen protects from UV light penetration. However, it is possible
that a specific optimal level or range of UVA and/or UVB light exposure is required to
influence specific immune modulation and subsequently allergic disease protection. Thus,
further investigations of detailed sunscreen use, including specific quantities (depth and
area of skin covered), and specific types of sunscreens used (including composition and
presence of any potential allergens, such as peanut/tree nut oils, which potentially could
lead to allergen sensitization via a disrupted skin barrier) could be useful in future studies.
Important related considerations also include geographical location (latitude) and other
influences on UV light penetration like air pollution levels [50].
When examining eczema severity, we did not find a significant inverse association
between SCORAD scores and direct UV light exposure measured by UV dosimeter. How-
ever, as eczema severity was only measured at the time of clinical assessment, we cannot
exclude that the child’s eczema may have been worse at other time points. Eczema severity
may have influenced parental decision to take their child outdoors and/or expose them
to sunlight, however most children in our study developed eczema after 3 months of age,
hence after the period of direct UV light exposure measurement by UV dosimeter.
Our findings, which indicate a vitamin D independent effect of early increased UV light
exposure on reduced eczema outcomes, have also been supported in animal models showing
that UV radiation leads to antigen-specific-T regulatory cell [51] and dendritic cell expansion
causing systemic immunosuppression irrespective of vitamin D [52,53]. Moreover, mast
cells [54] and regulatory B-cells affecting dendritic cell mediated T-cell activation, are also
involved in UV exposure triggered immunosuppression [55]. A study in mice by Gorman
et al. demonstrated that vitamin D was not essential in mediating the immunosuppressive
effects of erythema UV-radiation on contact hypersensitivity responses [56].
While we found associations with early childhood eczema outcomes, the measurement
of direct UV light exposure levels via UV dosimeter failed to show any influence on other
early childhood allergy outcomes. However, as this was an exploratory analysis of data
collected as part of a double-blinded RCT investigating the effect of infant oral vitamin D
supplementation for the first 6 months of infancy on allergic disease outcomes, and not the
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primary aim of the RCT, this UV light exposure levels analysis was likely underpowered to
assess associations with other early childhood allergy outcomes.
Interestingly, our longitudinal data analysis also revealed a protective link between
parent-reported time spent outdoors (specifically time spent in the sun) on wheeze out-
comes. Previous cross-sectional observational studies have described an inverse association
between vitamin D status and wheeze outcomes or atopy in childhood [57–60] and longi-
tudinally this finding was also supported by Hollams et al. showing that over a 10-year
period, the number of times a child was found to be deficient in vitamin D was positively
associated with the risk for eczema, sensitization, asthma and wheeze at age 10 years [61].
However, none of these previous studies evaluated UV light exposure in addition to vita-
min D status. Hence, while not specifically examined in these previous studies, it remains
possible that vitamin D independent UV-light induced effects may be responsible for their
associations with wheeze outcomes.
It is important to remain mindful of the harmful effects of UV light exposure when
reporting these potential beneficial effects—including skin damage and malignancy. Bal-
ancing the benefits and harms of UV light exposure will likely be an active and essential
research area of interest for years to come, especially with increasing urbanization and
even global pandemics leading to less time spent outdoors.
5. Conclusions
Exposure to UV light in early infancy appears to be beneficial in reducing the risk of
eczema development in early childhood. The immunomodulatory effects of UV light are
also likely to be important for other immune-based diseases across the life course. Further
research in large birth cohorts is required to address this, and to determine optimal levels
and patterns of sunlight exposure in infancy and early childhood, and how to balance the
potential advantages with risk of adverse effects such as skin damage and cancer outcomes.
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